Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJonsson Comprehensive Cancer Center
About this trial
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
Eligibility criteria
Qualifiers
Participant has provided informed consent prior to initiation of any study specific activities/procedures.
Male or female ≥ 18 years of age and willing and able to provide informed consent.
Low and intermediate grade neuroendocrine carcinoma (including carcinoid and atypical carcinoid)
Gastroenteropancreatic NEN
Disqualifiers
Diagnosis of SCLC (with the exception of SCLC transformed from previously-treated NSCLC) or NEPC.
Tumor specimen is not evaluable for DLL3 expression or tumor has DLL3 surface expression < 1% by immunohistochemistry.
Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.
Evidence of interstitial lung disease or active, non-infectious pneumonitis. Exception: pneumonitis related to prior radiation therapy that is grade 1 and stable or improving without treatment.
Trial design
Treatments tested in this trial
- Tarlatamab treatment
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Jonsson Comprehensive Cancer Center
Lead sponsor
Amgen
Collaborator
Source ClinicalTrials.gov